text: Decent game, but some of the frustrating game-play mechanics will kill you more often than the zombies will!User Rating: 7 | Dead Rising X360By docwoo | Review Date: September 7, 2006 I've been playing Dead Rising for about a week now, and I can honestly say that it's one of the most frustrating games I've ever played! First, I'd like to take this opportunity to issue a warning: anyone who hated those awful "escort" missions in other action/adventure games probably won't like Dead Rising very much! Remember those missions in Resident Evil 4 where you had to escort the President's daughter halfway across the game without getting her killed? Or the missions in Metal Gear Solid: Sons of Liberty where you had to do the same for Otocon's sister? Remember how furious you were when those characters kept getting themselves killed because the AI was too dumb to keep them out of harm's way? Well, I've got news for you: a LOT of the action in Dead Rising involves escorting characters with the very same dumb AI. You'll pull your hair out time and time again as characters you're trying to escort keep running into walls or take several minutes just to figure out how to get through an open doorway. People who buy this game because they're looking forward to exploring the HUGE mall will also be dissappointed. You only have a certain amount of time to complete the missions in the game, which doesn't leave much time for exploring. Finally, the save system is one of the worst I've ever seen! The save points are spread so far apart from each other, that you'll often win a hard boss fight only to be killed on your way to the next save point! Oh yeah....Otis calls wwaaayyy too much! Overall, this is a good game, but play at your own risk!


text:
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Q3 2007 Earnings Call
November 5, 2007 5:00 pm ET
Lisa Barthelemy - IR
Uli Hacksell - CEO
Tom Aasen - CFO
Alan Carr - Needham & Company
Ajim Tamboli - Lehman Brothers
Joe Pantginis - Canaccord Adams
David Amsellem - Friedman Billings Ramsey
Patrick Moriarty - Fortis Bank
Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2007 Financial Results Conference Call. My name is Melanie, and I'll be your coordinator on today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session toward the end of today's call. (Operator Instructions).
I would now like to turn the presentation over to Ms. Lisa Barthelemy, Director of Investor Relations at Acadia Pharmaceutical, who will review the Company's forward-looking statements. Please proceed.
Lisa Barthelemy
Good afternoon, and welcome to the Acadia Pharmaceutical third quarter 2007 financial results conference call. This call is being recorded, and an archived copy will be available on our website at www.acadia-pharm.com through November 19.
Before we proceed, I would like to first remind you that during our call today we will be making a number of forward-looking statements, including statements regarding our anticipated financial results and our research and development programs. These forward-looking statements are based on current information and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors and other risks associated with our business can be found in our filings made with the SEC, including our annual report on Form 10-K for the year ended December 31, 2006, and subsequent filings. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date. Acadia disclaims any obligation to update these forward-looking statements.
It is now my pleasure to turn the call over I'll to Dr. Uli Hacksell, our Chief Executive Officer.
Uli Hacksell
Thank you, Lisa, and let me take this opportunity to thank all of you for joining us on today's conference call. Also joining from the Acadia today are Dr. Roger Mills, our Executive Vice President of Developments, and Thomas Aasen , our Chief Financial Officer.
I will begin the call by covering some of our recent highlights. I will then ask Tom to review our financial results for the third quarter, and following these remarks we will briefly review our clinical programs. We will then open the floor to your questions.
Before we begin, and on behalf of all of us at Acadia, I would like to thank the financial community for their support and concern for our employees during the recent fire in San Diego. While many of the employees were among the large numbers temporarily displaced, we are fortunate to be able to say that our physiologist and the homes of our employees were untouched by the fires. Again, your messages and thoughts very greatly appreciated.
Now, even the third quarter, we continue to make solid progress with the ongoing clinical trials in our most advanced proprietary clinical programs. This includes the first pivot trial in our Phase III program with Pimavanserin, for the treatment of Parkinson's Disease psychosis, and our Phase IIb trial with ACP-104, for the treatment of Schizophrenia.
We started both of these key trials during the summer, and our development teams had worked diligently to get the initial clinical trials fully up and running, and advanced patient enrollments.
Meanwhile, following completion of the full analysis of our Phase II Schizophrenia co-therapy trial with Pimavanserin earlier this summer, I'm excited to report that we are preparing to present this data in collaboration with Dr. Herbert Meltzer at the ACNP annual meeting to be held in Boca Raton, Florida from December 9th-13th.
Given the prominence of this meeting in the neuropsychiatric community, we believe that this is the ideal venture for the presentation of the data, highlighting the full analysis of this Phase II trial.
We recognize that the attendance at the ACNP meeting is generally limited to ACNP members and designated sponsors. Therefore, we have also arranged to host an analyst and investor meeting in New York City on Friday, December 14th, immediately following the ACNP meeting, in order to provide the investment community with the opportunity to attend presentations on the full analysis from this exciting Phase II trial, and have access to leading clinicians in the area of schizophrenia.
In addition to the progress we have made in our advanced clinical programs, our strong balance sheet that provides us with a solid foundation to advance our clinical pipeline and execute on our growth strategy. We remain dedicated to providing meaningful improvements to patients who suffer from neuropsychiatric, and other CNS, disorders.
Before we review our clinical programs and our upcoming milestones in more detail, let me turn the call over to Tom to discuss our recent financial results.
Tom Aasen
Thank you, Uli. I will provide you with a brief overview of our financial results for the third quarter, was reported in our press release and Form 10-Q issued earlier today. Once again, I am pleased to report that our financial results for the quarter were in line with our expectations, reflecting the planned investment in our advanced proprietary clinical programs.
We reported a net loss of $16.0 million, or $0.43 per common share, for the third quarter of 2007, compared to a loss of $11.3 million, or $0.38 per common share, for the third quarter of 2006. We continue to maintain a strong cash position, closing the third quarter with the total of $141 million in cash and investment securities.
Let's briefly look at some of the components of our third quarter results. Our revenues totaled $2.0 million for the third quarter of 2007, compared to $1.9 million for the third quarter of 2006, and were once again comprised of revenues from our collaborations with Sepracor and Allergan, as well as agreements with other parties.
Research and Development expenses totaled $16.9 million for the third quarter of 2007, including $805,000 in stock-based compensation, compared to $15.5 million for the third quarter of 2006, including $550,000 in stock-based compensation. The increase in R&D expenses was primarily attributable to increased costs associated with the ongoing clinical trials in our advanced proprietary clinical programs, including the Phase IIb trial in our program with ACP-104, and the pivotal Phase III trial in our program with Pimavanserin for Parkinson's disease psychosis.
External service costs increased to $9.7 million for the third quarter of 2007, from $9.0 million for the comparable of 2006.
General and administrative expenses totaled $2.9 million for the third quarter, and were comparable to the third quarter of 2006.
Finally, let me update you on our cash outlook. We believe that with our current balance sheet, we are well positioned to continue to advance our proprietary clinical pipeline and execute on our business strategy.
We continue to expect that our cash and investment securities will be greater than a $120 million at December 31, 2007, and that our existing cash resources including expected payments from collaborators will be sufficient to fund our operations through 2009.
I will now turn the call back over to Uli.
Uli Hacksell
Thank you, Tom. Let me now review our programs in more detail. Acadia's pipeline includes five mid- to late-stage clinical programs. In our most advanced program, we are in Phase III development with Pimavanserin for the treatment of Parkinson's Disease psychosis.
Earlier this year, we reported positive top line results from the Phase II trial in our program with Pimavanserin, as a co-therapy for Schizophrenia.
We also have two proprietary Phase II stage clinical programs, which are ACP-104 for the treatment of Schizophrenia and Pimavanserin, for the treatment of sleep maintenance insomnia.
We have retained worldwide commercialization rights for all four of these proprietary programs. In addition, we have a neuropathic pain program in Phase II clinical trials in collaboration with Allergan.
My remarks today will mostly focus on our two advanced schizophrenia programs and our Phase III Parkinson's disease psychosis program
Let me start by discussing our program with Pimavanserin as a co-therapy for schizophrenia.
Despite the commercial success of [listing] antipsychotics, which exceed $16 billion in worldwide sales, current drugs that are used to treat schizophrenia and related disorders have substantial limitations, including severe side effects and inadequate efficacy.
We believe that good co-therapy with Pimavanserin, combined with a submaximal dose of atypical antipsychotics, can significantly improve the way schizophrenia and related disorders are treated today.
As mentioned earlier, we look forward to presenting data from our Phase II schizophrenia co-therapy trial with Pimavanserin in collaboration with Dr. Meltzer at the upcoming 46th Annual Meeting of The American Society of Neuropsychopharmacology to be held in Boca Raton, Florida in December.
Dr. Meltzer's presentation will highlight findings from the full analysis of our Phase II co-therapy trial. The full analysis confirmed the robustness of the top line results reported in March. This demonstrated important advantages of co-therapy with Pimavanserin when combined with a submaximal dose of risperidone.
These advantages included enhanced efficacy, a faster onset of antipsychotic action and an improved side effect profile. The analysis also provides additional data in support of the benefits of Pimavanserin co-therapy and has served to further increase our excitement regarding the medical and commercial potential of Pimavanserin.
Immediately following presentation on the Phase II data at the ACNP meeting, we will host an analyst and investor meeting on Friday, December 14th in New York City. The meeting will feature presentations by Acadia and key opinion leaders of data from our Phase II schizophrenia co-therapy trial with Pimavanserin, along with presentations of our Phase III program with Pimavanserin for PDP or Phase II program with ACP-104 for schizophrenia and our other discovery and development activities. We'll be providing further details regarding our analyst and investor meeting later on this month.
I should also note that we're planning to have a number of additional data presentations related to our Phase II schizophrenia co-therapy trial at future medical meetings. For example, we have an abstract accepted for presentation at the 14th winter workshop on schizophrenia bi-polar disorders to be held in Montreal Switzerland in early February this next year.
In addition to presentation some of clinical data, we recently presented preclinical data, highlighting the benefits of Pimavanserin co-therapy at the 37th annual meeting of the society for neuroscience held in San Diego.
This data show that Pimavanserin potential to be a action of several of the most commonly used atypical psychotic agents in animal models predictive psychotic activity. And that we also reversed the adverse effects of these some pshychotic agents on cognitive function. This results suggest that the positive timings from clinical studies, evaluating Pimavanserin co-therapy with Risperidone maybe applicable to a wide range of antipsychotic drugs.
You may recall that the following completion of the full analysis of the Phase II schizophrenia co-therapy trial, we indicated that we had initiated our process to explore potential strategic alliances during the summer. This process involves thoroughly exploring our commercial opportunities with Pimavanserin, but the focus on ensuring that any alliance captures the proper commercial value for ACADIA as well as strong involvements and incentives for both parties.
Once again, you can appreciate that as we conduct our process we are not providing specific details regarding our partnering process, discussions or potential timing. What we can say is that we have been very pleased to see the positive and enthusiastic reaction from both in medical and pharmaceutical communities and the strong level of interest from potential partners to evaluate this opportunity.
We are also excited by the results of the full data analysis, which only increased our confidence regarding the potential Pimavanserin to pay significant drove in the treatment of schizophrenia and related disorders.
It's also important to note that while we explore our opportunities to optimize the commercial value of these assets, we'll continue to proceed in Phase III development with Pimavanserin as a treatment for Parkinson's disease psychosis. Many of these targets and activities that we are conducting in this Phase III program may be leveraged to support the development of Pimavanserin in other indications. In other words we continue to advance the development program of Pimavanserin across indications.
Let me now turn to our second schizophrenia program which is ACP-104, as a stand-alone treatment for schizophrenia. ACP-104's unique pharmacological profile combining m11 muscarinic agonist, 5-HT2A inverse agonist, and D2 and D3 partial agonist provides the potential for a superior atypical and psychotic efficacy profile with enhanced cognition. Current treatments are generally not effective in addressing negative symptoms and are also not effective or may in fact worsen cognitive disturbances associated with schizophrenia.
We are pleased with the progress of our ongoing Phase IIb trial that we initiated in late June this year. The environment for conducting schizophrenia trials continues to be favorable and we have seen strong interest in the trial by investigators and patients alike.
We believe that the solid progress that we are experiencing this to Phase IIb trial, is a reflection of the critical need for new and the improve therapies for patients with schizophrenia and the potential for ACP-104 to provide a superior efficacy profile with enhanced cognition.
Let me briefly review the design and objectives of this product. Our Phase IIb trial is a multi-center, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of ACP-104 in approximately 250 patients with schizophrenia who are experiencing an acute psychotic episode. Patients in this trial are randomized to three different study arms, which include two different doses of ACP-104 administered twice daily, 100 mix and 200 mix and one placebo.
The primary endpoint of the trial is antipsychotic efficacy as measured using the Positive and Negative Syndrome Scale, or PANSS, an industry standard rating scale commonly used in registrations schizophrenia products.
I am pleased to report that the progress today in this Phase IIb trial should allow us to complete the study ahead of our initial expectations. We currently anticipate reporting top line results from this trial in the third quarter of 2008.
Recently, Acadia scientists also made presentation of preclinical data on ACP-104 at the Annual Meeting of the Society for Neuroscience. These data show that ACP-104 has a superior profile in animal models of cognitive function and proteins activity in models predictive of antipsychotic efficacy.
We remain excited about the potential of ACP-104 to be great treatment for schizophrenia that can address one of the largest unmet medical needs associated with the disease.
Let us now turn to another program that we are also very excited about, and that is our Phase III clinical program with Pimavanserin as a treatment for Parkinson's disease psychosis, or [PDP].
PDP is the debilitating neuropsychiatric disease that occurs in up to 40% of patients with Parkinson's disease. There currently is no drug approved in the United States for the treatment of PDP despite the fact that this is a very serious condition characterized by disturbing hallucinations and delusions.
In fact, PDP is the most common factor leading to nursing home placements of patients with Parkinson's disease.
We believe that Pimavanserin is well positioned to be an important first-in-class treatment for PDP.
We are pleased to have advanced this program into Phase III with the initiation of our first pivotal trial in June this year.
Let me now take a moment to review the design and objectives of the study.
This Phase III trial is a multicenter, double-blind and placebo-controlled study that is designed to evaluate the safety and efficacy of Pimavanserin in approximately 240 patients with PDP.
Patients in this study are randomized to three different study arms, including two different doses of Pimavanserin 10 mg and 40 mg and one placebo arm.
Patients receive oral doses of Pimavanserin or placebo once daily for six weeks, in additional to stable doses of their existing dopamine replacement therapy. The primary endpoint of the trial is antipsychotic efficacy as measured using the scale for the assessment of positive symptoms or SAPS. Psychosis associated with Parkinson's disease is manifested mainly by positive symptoms, specifically hallucinations and delusions.
The SAPS is the widely accepted tool to measure positive symptoms and is considered the most appropriate scale to measure the psychosis in Parkinson's disease. Motoric tolerability is an important secondary endpoint in the trial and is measured using the Unified Parkinson's Disease Rating Scale, or UPDRS. We are pleased with the continued progress made by Roger and his team in our ongoing Phase III trial.
Our development team has worked diligently to get the initial trial sites up and running, to advance recruitment of patients at clinical centers located in the U.S. We continue to bring on new trial [science] including centers located throughout Europe where we anticipate recruiting patients imminently.
Additionally, patients who complete the Phase III pivotal trial have the opportunity to enroll in an open-label safety extension study. This allows for continued treatment of these patients, while providing data to support our safety requirements.
Importantly, we also see high enthusiasm from the U.S. and European investigators, partly eager to find the treatments for this debilitating disease.
I am pleased to note that our Phase III development program with PDP is progressing according to plan. Given the size of this patient population in relation to schizophrenia and the fact that this is a pivotal trial, we currently expect to report top line results from this Phase III trial during 2009.
As a reminder, our Phase III [program] in PDP consists of two pivotal efficacy trials and a standard safety package. In addition to our focus on getting the first pivotal trial fully up and running in both the U.S. and Europe, we are conducting site planning and other start-up activities in preparation for initiating the second pivotal trial.
We trapped around these trials in a [stagged] parallel fashion and we believe that we will be able to leverage the investment from the first trial to compress the development timeframe for the second pivotal trial.
Along with the advancement of our clinical programs, we continue to make good progress in our collaborative programs, including our Phase II program in neuropathic pain with Allergan. In addition earlier in the third quarter, we announced that in our next collaboration with Allergan, we advanced our muscarinic agonist for glaucoma into the clinic.
Our productive discovery of gene continues to provide us with the robust pipeline and drug programs to fuel our development efforts.
We are proud of the significant milestones that we have achieved so far this year including our transition to a Phase III stage company with Pimavanserin, the announcement of positive results from our large Phase II schizophrenia co-therapy trial, the investigation of our Phase IIb trial with ACP-104 and the strengthening of our balance sheet.
We believe that we have an exciting road ahead of us and we look forward to continue our momentum. We remain focused on a number of key objectives that we believe provide the potential to drive significant shareholder value for Arcadia. This includes our efforts to explore potential strategic alliances to optimize the commercial opportunity around our schizophrenia co-therapy program to advance our Phase III PDP program and to complete our Phase IIb clinical trial with ACP-104.
We also look forward to presenting the full data set from our Phase II schizophrenia co-therapy trial in December. We hope that many of you will have the opportunity to join our inaugural analyst and investor meeting in person or via webcast on December 14 to see this exciting data and to gain a deeper appreciation for the potential of our pipeline on next generation therapies for patients who suffer from neuropsychiatrics and other CNS orders.
That completes our update and we will now be happy to entertain any questions that you may have.
Question-and-Answer Session
(Operator Instructions). And our first question comes from the line of Alan Carr with Needham. Go ahead.
Alan Carr - Needham & Company
Hi good afternoon everyone.
Uli Hacksell
Hi there.
Alan Carr - Needham & Company
Hi, yeah, sounds like you're making some progress with the Pimavanserin in PDP and that you've that enrollment is, I guess little bit more clear here in terms of time lines. I was wondering if you can give any more detail on when you think you might get the second one started? And has your view changed, as whether or not this one is going to be exactly the same as the first or you are going to – are there going to be any differences between the two trials.
Uli Hacksell
Roger, may be you can give a short-term answer to that question.
Roger Mills
Yeah, thanks Uli. So Alan, I think this will be the strategy was to position the two studies in a staggered manner, but obviously in parallel. So as we've been doing lot of work in getting the first study up and running, we've been doing the preparatory work for and that's well underway. So we will anticipate starting that study probably soon.
Alan Carr - Needham & Company
In the first half '08 probably, or even by yearend, do you think?
Roger Mills
Actually starting, I won't give the exact time but it will be a lot faster than the end of '08 I can assure you, its.
Alan Carr - Needham & Company
At first half?
Roger Mills
Probably soon.
Alan Carr - Needham & Company
Okay. And I guess that we missed, but didn't ask about partnering for Pimavanserin and can -- I am wondering if you can characterize those discussions to any degree as to whether or not, are you finding any hesitation for patterning this drug because its an agent as apposed to a standalone drug or are there particular financial term that you are looking for?
Uli Hacksell
Yes, so let me try to answer that question. First of all, as we have indicated following the completion of the full analysis of our trial, we initiate this process to explore potential strategic alliances that really can help us to optimize the value of Pimavanserin. What we can say is that we have been very pleased with the positive reaction on the Phase II data from both the medical and pharmaceutical communities. And what I can tell you is that following the full analysis of the data from this trial, we are more excited than ever above the commercial potential for Pimavanserin and we believe that this excitement is also evident in this captions with potential partners.
Now, when it comes to the kind of deal that we really are aiming for, it's clearly -- we are looking for something that can help us to really complete the comprehensive registration program that will maximize the value of this opportunity on the market. And we believe that this drug has a -- represents a great commercial opportunity
I should also mention that, in general terms, our strategy is to try to retain rights to participate in the commercialization in areas such as Parkinson's disease psychosis, in the U.S. And we certainly want to end up with the deal that has the right commercial aspects in it has strong involvement and incentives both for us and our potential partners.
Alan Carr - Needham & Company
Do you sense any hesitation by your potential partners in letting you all participate?
Uli Hacksell
As I said before, we don't want to go into specific details of our process or these discussions. What I can say is again that we are excited and we see excitement from our potential partners as well.
Alan Carr - Needham & Company
Okay. Thanks very much
Uli Hacksell
Our next question comes from the line of Ajim Tamboli with Lehman Brothers. Go ahead.
Ajim Tamboli - Lehman Brothers
Good afternoon. On the pimavanserin presentation at the ACNP meeting, following the data you've realized to-date, what incremental details can we expect to receive in December?
Uli Hacksell
Roger, do you want to take your shot on that?
Roger Mills
Yeah, thanks Uli. I think first thing is, I just want to stress is that when we did the top line data, those were very pretty comprehensive analysis that we done prior to that. So those – the messaging that we've put out there to-date is being confirmed by the additional analysis that we have done, a lot of it was just robust and striking. I think what you'll see is a broader aspect of some of the data behind the messaging that we put out to-date really reaffirming the key aspects of that the efficacy on the PANSS scale which is very clinically meaningful and was driven not by any one elements of that, but across the Board. The accelerated response that we saw and the benefits in the side effect profiles with the weight gain, prolactinemia, there will be some data on the akathisia and weight gain. So I think you are going to see written essentially the background to the messaging that we put out to-date.
Ajim Tamboli - Lehman Brothers
So I would have to assume no surprises other than the supported data we've seen the date including on the side effect profile?
Uli Hacksell
Yeah, there are no surprises that we have that which is very reassuring all our business analysis confirmed that the position that we reported early this year.
Ajim Tamboli - Lehman Brothers
Okay, great. And then on the ACP-104 Phase IIb trial on schizophrenia, can you tell us how many patients have been dose to-date and what the weekly blood monitoring requirements are, and whether we have seen additional cases of leukopenia and any suggestion of agranulocytosis?
Uli Hacksell
Yeah again Roger, I think this is a question for you.
Roger Mills
Okay, thanks, Uli. We are not giving specific information on the numbers of patients that are enrolled in this study. Apart from saying that we are very pleased with the performance on the study and we are very pleased with the progress that we are making there. And I think as Uli mentioned earlier, we expect to report top line results in the third quarter of next year of '08.
In terms of the monitoring in the study, we're doing a pretty standard monitoring which does include hematological data and that is pretty standard and we're moving along another, and as I said we are very pleased, we remain very pleased with the progress in the study.
Ajim Tamboli - Lehman Brothers
Is that weekly or biweekly?
Roger Mills
It's weekly.
Ajim Tamboli - Lehman Brothers
Weekly, okay.
Uli Hacksell
(inaudible) that we're following a very rigorous kind of blood monitoring.
Ajim Tamboli - Lehman Brothers
Right. Okay, great. And then finally, Uli, I guess, as you see think about partnering given that we have had data for few moments now for Pimavanserin, how do you weigh that versus completing a partnership versus I guess taking the program forward here in terms of timelines?
Uli Hacksell
Yes, Ajim, as I have said, many, many times, I think it's ideal to have a commercial partner involved in the design of the complete Phase III program from a commercial point of view because if you want to make sure that you do the right start, it's from a commercial point of view in the area of schizophrenia. So clearly, we think that's a very interesting aspect of these discussions and that we're having now.
We've not excluded them that we may do additional schizophrenia start-ups I have said, but again, I think the ideal kind of scenario is to think to have a partner helping us to complete the registration studies that will enable us to maximize the commercial opportunity around Pimavanserin.
Roger Mills
And you also may add to that we have the Parkinson's program already ongoing, not only we continue to generate important clinical data, but we also have the rest of the Phase III program which is appearing in parallel with that clinical program designed obviously to provide a package registration at the end.
Ajim Tamboli - Lehman Brothers
Great. Thanks for taking the questions.
Uli Hacksell
Our next question comes from the line of Joe Pantginis with Canaccord Adams. Go ahead.
Joe Pantginis - Canaccord Adams
Hi, guys, good afternoon. Thanks for taking the call.
Uli Hacksell
Hi, Joe
Joe Pantginis - Canaccord Adams
Hey, just quick question on the Phase II data, the top line data, you guys presented or made the statement that even though you couldn't get into as much detail as you can in the upcoming final data that significantly impacted the negative symptoms. I was just wondering, I know you can't get into the specifics now, but can you give us why it's important relative to what other treatments have not been able to show in impacting negative symptoms?
Uli Hacksell
Do you want to answer that Roger?
Roger Mills
You want to give the background first.
Uli Hacksell
Yeah. Let me take a step back and look at schizophrenia therapy in general. So remember we have three symptom domains in schizophrenia. We have positive systems, that are the hallucinations and delusions, which are well treated by almost antipsychotic agents. Then you have the negative symptoms, which are poorly treated, or perhaps even worsen, by some of the antipsychotic drugs you see today. And the negative symptoms consist of social withdrawal etcetera and apathy in general. And then you have the third symptom domain, which is the cognitive deficit induced by the disease and probably worsened by all existing antipsychotic agents. So two of the untreated, or very poorly treated areas, of schizophrenia symptoms are the negative symptoms and the cognitive deficits And that why it's really interesting to look in particular at improvements in negative symptoms like cognitive deficits with a drug like pimavanserin.
Now, before I let Roger to answer your question I should also mention that in the data that we presented at the neuroscience meeting just recently, we showed that, while all the atypical antipsychotic drug, in fact, worsen for example, cognition. Pimavanserin is able to reverse that effect, that negative affect on cognation and we think that cognitive aspects of Pimavanserin therapy may extend also in the negative symptom domain. So that is essentially the back ground that we have from the clinical experience with atypical antipsychotic drugs and with pharmacological experiments in the same area. Roger.
Roger Mills
Thanks Uli. I think what we saw in the Phase II study are those positioned appropriately to begin with, this was looking at the full PANSS scale in a particular population of acute schizophrenic patients. If one wishes to look specifically the negative symptoms or more probably use a more stable population and perhaps some one would want to use a more specific scale such as the SANS scale, which is the negative side of the SAPS scale that we are using in Parkinson's. And you would specifically design a study to really highlight those aspects and this study wasn't specifically designed for that reason, however, within the overall aspect to PANSS clearly the end side of the PANSS related to negative symptoms and is really set as specific demands to look at them.
What we saw in this study was a very nice robust affect, not only on the positive symptomatology of the disease, but also, importantly, on the negative symptoms and which is very encouraging for us. So we didn't see one particular element driving the results, it was across the spectrum of the disease that one saw a benefit.
But in terms of highlighting that in further development one would probably wish to use a more specific scale and the different design of the study to bring those potential benefits to the full.
Joe Pantginis - Canaccord Adams
Okay great. Thanks a lot that was helpful.
Our next question comes from the line of David Amsellem with Friedman Billings Ramsey. Go ahead.
David Amsellem - Friedman Billings Ramsey
Hi, thanks for taking my questions. So just on Pimavanserin you have right now $140 million in cash realized that you are looking for the right commercial partner to be in place, but in the interim do you envision running any additional, say Phase IIb type studies, say with other atypical antipsychotic or do you plan to move forward with any other indications in terms of running any exploratory studies. I am just trying to get a sense of what you plan to do in terms of clinical trials for Pimavanserin in the interim while you are trying to secure partnership?
Uli Hacksell
Again, just to reiterate of what Rogers said before, we are moving forward quite aggressively with Pimavanserin Phase III clinical studies for Parkinson's disease psychosis. We think what we do in that registration program will benefit Pimavanserin development for other indications as well.
So, we haven't indicated to them what kind of additional studies we may do in the future. We haven't said that we may not do anything else. But, again that's something that we are thinking about clearly.
Rogers Mills
I think it's also important that the study that we did provide a really good proof concept result and therefore I think, as you are indicating, [one good look at] doing other specific drugs to combine with. But I think, as Uli had mentioned earlier, it's important that as we embark on further studies that we do so with a view to the maximizing the value of this compound in the marketplace.
And that's a very, one of the key elements of why we are looking at partnership, so that we can specifically position further studies in order to get the maximum value when the drug hits the marketplace.
David Amsellem - Friedman Billings Ramsey
And then a second question if I may on Pimavanserin, can you say what portion of the sites in the Phase III study in PDP are U.S. versus ex-U.S?
Rogers Mills
It is close to 50% a little more in the U.S. in the first study, but it's pretty close to sort of 50/50 overall.
David Amsellem - Friedman Billings Ramsey
Okay. Alright, thanks.
Our final question comes from the line of Patrick Moriarty with Fortis. Go ahead
Patrick Moriarty - Fortis Bank
Hi, good evening. Thanks for taking my questions. I have a quick follow-up on the ACNP data to be looked at. In terms of the efficacy you have given the responder analysis using a 20% reduction. Are you going to look at the magnitude of response in this presentation, in other words look at may be 25% , 30% PANSS reduction at the various standpoints?
Rogers Mills
We not specifically stated what we are going to present at that meeting. We have I think thought previously number of business check, obviously warm looks at the different aspects of what would be a responder, but I am not so certain that we have decided exactly what we are putting into that presentation yet.
Patrick Moriarty - Fortis Bank
Is it possible to comment on the robustness of response side?
Rogers Mills
Only that we are comfortable the result we have reported is confirmed as we said earlier. All the results are confirmed by the various business checks that we've done.
Patrick Moriarty - Fortis Bank
Okay, great. Thank you
Rogers Mills
Ladies and gentlemen, that does conclude our question-and-answer session for today. Dr. Hacksell, please proceed to closing remark.
Uli Hacksell
So thanks again to everyone for joining us on today's call and for your continued support. We look forward for the opportunity to update you in the future on our ongoing process. Thanks.
Thank you for your participation in today's conferences call. This concludes the presentation. You may now disconnect. Have a good day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!

subset: commoncrawl


text:
Welcome, Guest!
Social marketing is being important and essential for now . Among the department of social marketing Facebook, twitter, Google + and more. But for make a...
Have you got something to say to the world? Has blogging been something you have considered taking on? WordPress has become the popular blogging standard on...
#islanders highlight of the week Frans Nielsen scores his first career hat trick against the Dallas Stars
security cameras
If one can not find out easy way to download tekken 6 for pc he can visit below the link. There is more app and software with games which are so fast and...
This is my real photo.
If you wan to go your final destination you have to work hard. I'm perfect that one can not lose in life if he do hard work.
I'm new member of this site,. When I entered i followed that the sites work so well and i can get my necessary more.
Games and sports are the parts of our life . And we can not lid a happy life with out it . So every body should take it.
Front Page
TCL Flyers
George Prax
Mark Trible
Rob McGowan
Cheryl Adams
Chuck Gaston Jr.
John Russo
Jordan Kuhns
Kyle Busch
Patrick Storto
Ron Guillet
BWP Staff
Grinder Threads
TCL Staff
Alicia Sprenkle
Anatoliy Metter
Andy Veilleux
Chris Bengel
Chris Reid
Daniel Spevak
David Collins
Erol Bal
Evan Pivnick
John Link
John Madonia
John O'Hara
Kim Pollock
Kory Wielenga
Steve Fetch
Lowell Williamson
Marco Perruzza
Bill Philp
Dan MacNeal
Mike Dusak
Mike Flannery
Phil T
Coach's Sister
Quinn Mell-Cobb
Scott Hannon
Scott Schmidt
Shane Blackburn
Steven Smeall
Yves Arsenault
Brad Butland
A.K. Bennett
Brad Butland
Brad Windsor
Bryan Wright
Drew Henn
Eric Huffman
George Royle
Greg Duley
Justin Doddie
Maggie Avila
Matt Cefalu
Nick Symon
Paul Kendall
Rachel Bellono
Robert D'Aurelio
Russell Dornisch
Shane Brennan
Ty Fisher
Message Boards
Shop Grinder Threads
Electronic Press
Grinder Threads
The Sports Roundup
Cowhide and Rubber
Habs Addict
Habs Eyes on the Prize
Hockey Independent
Hockey Inside/Out
Japers Rink
Philly Phaithful
Pro Fantasy Sports Leagues
TCL Flyers
TCL Isles
TCL West
Yves on Habs
Contact Us
Hobey Baker
Early 2012-13 Hobey Baker Award Big Board
July 23, 2012
Steve Fetch
1 Comment
Last year Minnesota-Duluth Senior Jack Connolly became the fifth Bulldog to win the Hobey Baker Award, rising above a group of very talented hockey players. Although he did not run away with the award, the fact that there were a number of worthy potential winners means only good things for the talent level in college hockey. This year is no different: there are a few players who first come to mind when thinking of potential Hobey winners, but no one favorite. But even though there is no favorite, there still needs to be a Big Board. Here is the first look at the leading contenders for college hockey's player of the year, the Hobey Baker Award:(no...
Continue Reading
Anaheim Mighty Ducks
Boston Bruins
Buffalo Sabres
Calgary Flames
Carolina Hurricanes
Chicago Blackhawks
Colorado Avalanche
Columbus Blue Jackets
Dallas Stars
Detroit Red Wings
Edmonton Oilers
Florida Panthers
Los Angeles Kings
Minnesota Wild
Montreal Canadiens
Nashville Predators
New Jersey Devils
New York Islanders
New York Rangers
Ottawa Senators
Philadelphia Flyers
Phoenix Coyotes
Pittsburgh Penguins
San Jose Sharks
St Louis Blues
Tampa Bay Lightning
Toronto Maple Leafs
Vancouver Canucks
Washington Capitals
Winnipeg Jets


text:
Sign in now to view, license and download this image or contact us to see this image without a watermark. Want to embed this image on a non-commercial website or blog? Learn more.
{{ title }}
{{ link.name }}Keywords
Golden Retriever Dog Lying On Sofa Closeup Stock Photo sb10069719y-001Dog,Sofa,Golden Retriever,Sadness,Pets,Relaxation,No People,Indoors,Laziness,Animal Themes,Comfortable,Cosy,Day,Colour Image,Horizontal,Looking Away,Lying On Front,One Animal,Photography,Three Quarter LengthPhotographer Janie AireyCollection: Digital Vision


text:
Immaculate condition Beck factory built speedster replica in German Racing Silver exterior, black full leather interior and black canvas Stayfast top. Fully optioned including... More
This Speedster ReCreation looks and drives like new, shows virtually no wear. It has the ever popular German Racing Silver exterior with new black... More
Beautiful combination of Tuxedo Black exterior with Dove Gray interior and new Black Stayfast canvas top completes the out ward beauty while the beastly... More
This is the most highly optioned Intermeccanica Convertible d/ Roadster ever built at their factory in Vancouver, Canada. The exterior is an exquisite GM... More
This Convertible d/ Roadster replica was built at the Intermeccanica factory in 1986. Featuring a refreshed high performance 1600cc VW Type 1 motor with... More
This Pristine Beck Speedster Replica carries the ever desirable Porsche Ruby Red and Whiskey Tan leather interior, tan canvas top combination. Hardly used with... More
Intermeccanica built less than 20 of these Convertible d Turbo Look RS replicas in the 1980s. Combining the taller windshield, roll up glass windows... More
Immaculate low mileage Ivory Speedster replica with full leather interior in black with ivory piping. Like new Stayfast black canvas soft top, side windows... More
This Carrera GT Outlaw Wide Body is the ultimate traffic stopper. The perfect outlaw look with nerf bars front and rear and a completely... More
The ever popular Ivory exterior with tan leather interior and black canvas soft top makes this1993 Intermeccanica factory built tubular frame convertible d one... More
The ever popular color combination of Ivory exterior, tan interior and tan top make this Speedster replica the car of choice for summer top... More
This is one unique, exotic Speedster replica. Gulf blue with black interior and black canvas soft top. Mid engine tube frame chassis supports an... More
Popular color combination of Tuxedo Black with Tan interior and Black canvas soft top. This low mileage speedster has the peppy 1776cc VW Type... More
This is a one off Porsche 356 Speedster/ 930 turbo custom tribute car. Eye grabbing orange metallic Glasurit paint with tan/beige leather seats,dash, door... More
Intermeccanica Convertible D replica built in December 1985. Signal red with tan interior and tan soft top. Loaded with options including Panasport wheels, roll... More


text:
The Global Intelligence Files,
files released so far...
Index pages
by Date of Document
Our Partners
Al Akhbar - Lebanon
Al Masry Al Youm - Egypt
Asia Sentinel - Hong Kong
Bivol - Bulgaria
Carta Capital - Brazil
CIPER - Chile
Dawn Media - Pakistan
L'Espresso - Italy
La Repubblica - Italy
La Jornada - Mexico
La Nacion - Costa Rica
Malaysia Today - Malaysia
McClatchy - United States
Nawaat - Tunisia
NDR/ARD - Germany
Owni - France
Pagina 12 - Argentina
Philip Dorling - Fairfax media contributor - Australia
Plaza Publica - Guatemala
Publica - Brazil
Publico.es - Spain
Rolling Stone - United States
Russian Reporter - Russia
Ta Nea - Greece
Taraf - Turkey
The Hindu - India
The Yes Men - Bhopal Activists
Sunday Star-Times - New Zealand
Community resources
courage is contagious
The Global Intelligence Files
On Monday February 27th, 2012, WikiLeaks began publishing The Global Intelligence Files, over five million e-mails from the Texas headquartered "global intelligence" company Stratfor. The e-mails date between July 2004 and late December 2011. They reveal the inner workings of a company that fronts as an intelligence publisher, but provides confidential intelligence services to large corporations, such as Bhopal's Dow Chemical Co., Lockheed Martin, Northrop Grumman, Raytheon and government agencies, including the US Department of Homeland Security, the US Marines and the US Defence Intelligence Agency. The emails show Stratfor's web of informers, pay-off structure, payment laundering techniques and psychological methods.
Released on 2012-10-18 17:00 GMT
Email-ID | 836074 |
Date | 2010-07-16 12:30:22 |
From | firstname.lastname@example.com |
To | email@example.com |
1) Folk-rock band Troitsa performs for first time at
2) Yeni Ozgur Politika Headlines 13 July 2010
The following is a list of news headlines from the Yeni Ozgur Politika
website on 13 July; to request additional processing, please contact OSC
at (800) 205-8615, (202) 338-6735, fax (703) 613-5735, or
3) Commentary Discusses Rise of Islamic Terrorism Across African Continent
Commentary by Stefan Simanowitz: "Kampala Bombings and Al Qaeda Activities
in Africa"
4) RSA Writer Says Holistic Approach Needed To Tackle Somalia's Al-Shabaab
Article by Anneli Botha: "Are the Ugandan Terror Attacks a Sign of Things
To Come From Al Shabaab?"
5) Kenya Dispatches Anti-Terrorism Detectives To Help Uganda Capture
Unattributed report: "Uganda Blasts: K enyan Detectives Join Kampala
Terrorists' Hunt"
6) Ugandan Police Warn Against Fresh Terror Attacks at Border Towns
Report by Dradenya Amazia: "Police Warns of Terror in Arua, Mbale"
7) Shalit Counter Aid Ship Heads From Netherlands To Sderot, Gaza -- Radio
Shalit Counter Aid Ship Heads From Netherlands To Sderot, Gaza -- Radio
Israel -- KUNA Headline
8) Xinhua 'Analysis': Can Clean Energy Help Boost U.S. Employment?
Xinhua "Analysis" by Matthew Rusling: "Can Clean Energy Help Boost U.S.
1) Back to Top
Folk-rock band Troitsa performs for first time at - Belorusskiye Novosti
Thursday July 15, 2010 07:50:39 GMT
Veteran folk-rock band Troitsa has performed for the first time at an
international art festival, Slavyanski Bazar in Vitsyebsk, which kicked
off in the northern Belarusian city at the end of last week, BelaPAN
The band played at more than 80 European festivals, earning significant
recognition in Germany, the Netherlands, Hungary, Portugal, Estonia and
The Vitsyebsk concert, which lasted almost two hours, was very warm and
lively. The rockers were encored three times.
'We had to perform at 80 festivals across the world, from Malaysia to
Portugal, to eventually play such a concert in our homeland,' Troitsa
frontman Ivan Kirchuk confided to the audience. The band played a
selection of new songs. 'We want to release a new CD, but we don-t yet
know where we will do it,' Mr. Kirchyk said.
Between songs, the frontman talked to the audience, telling a story about
a Belarusian medieval marriage during which he said around 400 songs were
sung. 'This is why, perhaps, our ancestors lived long lives and never got
divorced,' he suggested.
(Description of Source: Minsk Belorusskiye Novosti Online in English --
Online newspaper published by Belapan, and independent news agency often
critical of the Belarusian Government)
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
2) Back to Top
Yeni Ozgur Politika Headlines 13 July 2010
The following is a list of news headlines from the Yeni Ozgur Politika
website on 13 July; to request additional processing, please contact OSC
at (800) 205-8615, (202) 338-6735, fax (703) 613-5735, or
firstname.lastname@example.com - Yeni Ozgur Politika Online
Thursday July 15, 2010 17:03:27 GMT
Arson of BDP (Peace and Democracy Party) District Chairperson's Car -
While an armed person in the crowd attending the opening ceremony of the
BDP building in Ankara opened fire randomly, the car of the district
chairperson, Adile Deger, was destroyed.
Son of Village Guard Commits Suicide - After arguing with his father ten
days ago, 18-year-old Tahir Basaran of the village of Hosner Qabilcewz
(Uluagac, Sason), shot himself with his father's gun and then died of the
Home Raids in Sert (Siirt) - Two nights ago percussion bombs were thrown
simultaneously at the Sert Cumhuriyet Police Station and Court House.
Following these attacks, 15 BDP and YDG (Patriotic Democratic Youth)
members was taken into custody during home raids.
13 Taken into Custody in Istanbul - A total of 13 people, two of them
children, were taken into custody during raids carried out by the police
against homes in the districts of Kagithane, Eyup, a nd Avcilar in
Reports Refute Atalay - Turkish Interior Minister Besir Atalay announced
that in the first six months of the year no rights violations had occurred
and no suits were launched against police officers.
Assimilation Failure Admission - Government Spokesman and Deputy Prime
Minister Cemil Cicek admitted that they had not been successful in their
assimilation efforts.
Four JITEM (alleged intelligence unit within Gendarmerie) Members Killed -
The HPG has announced that while their guerrillas had killed four JITEM
members who were scouting out the area in a rural area near Sax,Wan
(Catak, Van), YJA Star (Free Women's Defense Forces) guerillas had
destroyed a vehicle carrying seven soldiers in the Perwari district of
Compensating for Justice! - According to the responses given by Turkish
Foreign Minister Ahmet Davutoglu to the formal inquiry questions put to
him by BDP Deputy Perwin Buldan, up until 1 January, 2009, a tot al of
27,398 applications had been made to the ECHR (European Court of Human
Rights) regarding Turkey, and a total of 110,569,523 TL had been paid in
compensation during the 2004-2009 time period.
BDP: Chemical Weapons Being Used! - BDP Deputy Osman Ozcelik said,
"Burning chemical weapons are being used in the armed confrontations, and
the bodies are being burned beyond recognition." He went on to say that it
is to cover up this fact that the bodies of killed guerrillas are not
being given to their families.
Injured Guerrilla Fight for Three Hours! - It was reported that a HPG
guerrilla lost his life in the rural area near Norsin, Bedlis (Guroymak,
Bitlis). The HPG stated that even though he was injured, the guerrilla
continued to battle for three hours against Cobra helicopters, heavy
weapons, and additional soldiers until he had used his last bullet.
Savagery Protested in London - Kurds who live in England and France
protested the desecration of the bodies of HPG guerillas who lost their
lives in Perwari and Semzinan (Semdinli).
TSK (Turkish Military Army) Violates Geneva Convention - By killing the
guerrillas it had taken captive and then desecrating their bodies, the
Turkish army has once again left a black mark on human history. Up to now
the PKK guerrillas have acted in accordance with the Geneva Conventions in
their treatment of soldiers and police they have taken captive.
Boycott Against Turkish Justice - PKK and PJAK (Free Life Party of
Kurdistan) member prisoners being held in Turkish prisons have decided to
boycott the Turkish justice system and, starting tomorrow, they will no
longer attend their trials.
A Drama School for Guerrillas - TiyatrAPOtamya, which carries out its
activities under the umbrella of the Martyr Sefkan School of Culture and
Art, has performed 16 plays in 10 years by transforming any mountain grove
in Kurdistan into scenery and any piece of rag into a costume.
Istanbul Hosting Young Directors - The increase in the number of short
film competitions in national and international arenas to which
competitors can apply is drawing attention. Istanbul is now hosting the
2010 International Teen Short Film Festival, a festival of films shot by
directors aged 13-19.
"They Are Not Ashamed of Killing Youths" - Saying that there has never
been a period in Turkey's history that was free of massacres, unsolved
murders, and violence, journalist Berat Guncikan said: "Turkey always
smells of newly dug soil and has never in its history been ashamed of the
deaths of youth."
"We Were Ashamed of Our Maleness" - In their reactions to the racist and
sexist remarks made by AKP (Justice and Development Party) Rize Mayor
Halil Bakirci regarding Kurdish women, a group of men who are members of
the ESP (Socialist Party of Oppressed People) said: "These words are a
reflection of the violence inherent in m ale domination, and these words
made us ashamed of our own maleness."
Aim Is to Increase Level of Freedom - In a statement they released
relative to the "Campaign to raise the struggle for freedom and overcome
the culture of rape," the Women's Commission of the Ankara province branch
of the BDP said: "The aim of our campaign is to heighten women's level of
Stopping Stoning Not Enough - The sentence of stoning to death given to
Sakine Ashtiyani by the Iranian Shariah regime was halted in the face of
the reactions of international human rights organizations, but she remains
in a state of danger.
"I Was Sexually Harassed by the Police" - TUBITAK (Scientific and
Technological Research Council of Turkey) employee Aynur Camalan applied
to the IHD (Human Rights Association) saying that she had been sexually
harassed by the police.
Victory of Spain - Spain beat Holland in the final match of the 2010 World
Cup w ith one goal that was shot during the overtime period, making this
the first time that Spain has taken home the cup. Even though this was the
third time that Holland was playing in the finals, the country was sorely
disappointed when it did not achieve a happy ending.
Muslim World Apathetic about Kurds - Sheikh Said and his 47 comrades were
commemorated in a ceremony in Dortmund, Germany, to mark the 85 th
anniversary of their execution. Participants in the event voiced criticism
of the Muslim world, which remains silent about attacks made on Kurds.
People's Meetings in Stuttgart and Pforzheim - Simultaneous people's
meetings were held in both Stuttgart and Pforzheim, Germany. Attendees
promised to raise the level of their resistance against the attacks.
"A Handful of Elitists Oppose Reform" - A referendum is being held in the
German state of Hamburg on the matter of education reform. Mehmet Yildiz,
a Hamburg Parliament Member of the Left Party , said that the reform is
being opposed by a handful of elitists.
Attacks Against Final Match Audiences: 64 Dead - At least 64 people were
killed in bomb attacks carried out in Kampala, the capital of Uganda, that
targeted the people who were watching the Holland-Spain final match.
NRW (Nordrhein Westfalen) Left Party Elects Administration - During the
past weekend, the Left Party elected its new party administration for NRW,
the biggest state in Germany.
Corruption on France's Agenda - The ring of French corruption, that
includes President Nicolas Sarlozy, is broadening daily. Very important
names from the country's worlds of politics and finances are popping up in
the corruption charges.
Germany Bans the IHH (Foundation for Human Rights and Freedoms and
Humanitarian Relief) - The German Ministry of the Interior has banned the
international humanitarian relief organization, the IHH, from carrying out
activities within the country. Kurdish News :
Sakik: The State Should Take Ocalan's Proposals Into Account - BDP Mus
Deputy Sirri Sakik says that it is Abdulalh Ocalan who can bring peace to
Turkey and he asked the state to listen to what Ocalan has to say.
Enemy of Kurdish Culture - Deputy Prime Minister Cemil Cicek has admitted
that the policy to assimilate the Kurds had failed. He said that they had
managed to teach Turkish to Nigerians, but were not able to teach it to
the people of Colemerg (Hakkari) and Amed (Diyarbakir).
PKK Member Prisoners Boycott Courts - PKK and PJAK member prisoners in
Turkey and Kurdistan stated that they will boycott the prosecutors and
will not attend their trials. The prisoners stated that everybody should
demonstrate their anger about the savage attacks and should not remain
"Democratic Autonomy Should be Discussed" - Levent Tuzel stated that
holding to the belief that the Kurdish issue can be solved with weapons
constitutes a danger for Turkey.
Unique Resistance - HPG guerrilla Yasar Dilmen fought against Cobra
helicopters for three hours in Norsin.
Spain Takes World Cup - Spain beat its competitor 1-0 in the final match
of the 2010 World Cup and, for the first time in its history, managed to
take home the championship. The match was played with a great deal of joy
and excitement and was broadcast live on many of the world's stations.
Dersim (Tunceli) Starts Early Harvest - The surge of military operations
and armed confrontations in the region are driving the people of Dersim to
harvest their crops early this year. The people are working in the fields
under the noise of helicopter and guns.
Mount Ararat Pleads for Care - Even though Mt. Ararat ranks as one of the
world's most important mountains, the mountain is becoming increasingly
polluted by the campsites set up there. Remzi Gegez, Chairman of the Bazid
(Dogubayazit) Environmental Preservation Association, is asking people to
behave with greater sensitivity to the environment.
Disease within Syrian Army - An unknown disease is spreading among the
Syrian army. At least 13 soldiers have been hospitalized and died in
military hospitals. The KCK-Rojava (Assembly of Communities of
Kurdistan-West) warned that the infectious disease is spreading rapidly.
Latest Zend Discusses Problem of Names of Months - The quarterly academic
journal Zend has published its Summer 2010 issue. This issue discusses the
problems related to the names for the months in Kurdish.
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
3) Back to Top
Commentary Discusses Rise of Islamic Terrorism Across African Continent
Commentary by Ste fan Simanowitz: "Kampala Bombings and Al Qaeda
Activities in Africa" - Daily Monitor Online
Thursday July 15, 2010 10:41:20 GMT
(Description of Source: Kampala Daily Monitor Online in English -- Website
of the independent daily owned by the Kenya-based Nation Media Group; URL:
Material in the World News Connection is generally copyrighted by the
source cited.Permission for use must be obtained from the copyright
holder.Inquiries regarding use may be directed to NTIS, US Dept. of
4) Back to Top
RSA Writer Says Holistic Approach Needed To Tackle Somalia's Al-Shabaab
Article by Anneli Botha: "Are the Ugandan Terror Attacks a Sign of Things
To Come From Al Shabaab?" - Institute for Security Studies
Thursday July 15, 2010 12:14:06 GMT
This was again demonstrated by the recent arrest and conviction of an
Australian-based cell linked to al Shabaab that planned attacks against a
military base in that country. Another example was the attempt by Mohammed
Muhideen Gelle (a Somali national allegedly linked to al-Shabaab) to kill
Kurt Westergaard (the cartoonist of the controversial Prophet Muhammad
cartoons) in Denmark early this year. Consequently intelligence agencies
(including from South Africa in the lead up to the World Cup) became
increasingly concerned with the threat posed by a small number of
individuals within the Somali expatriate community.To expand its
geographic scope of operations, al Shabaab has gone on a recruitment
drive. It is aggressively trying to recruit Somali expatriates from
western countries (including the United States, Canada, United Kingdom,
Sweden, The Netherlands), as well as ha rdened fighters from the conflicts
in Iraq and Afghanistan. It has also openly aligned itself with al-Qaeda
in an attempt the garner greater legitimacy and more supporters.Responding
effectively to this growing threat emanating from the ongoing strife in
Somalia will not be easy. It is hoped that those driving the international
and regional responses will learn from mistakes made around the world in
preventing and combating terrorism in the past. A short-sighted approach
that relies on 'eliminating' suspected terrorists will not work.
Counter-terrorism actors working in the sub-region must also address the
broader underlying causes that have fuelled the conflict in Somalia for
years.Failure to do so will simply strengthen the appeal of al-Shabaab and
introduce a new cycle of terrorism. A more holistic approach, one which
relies on building strategic partnerships with key local actors, and that
aims to find a lasting road to peace in Somalia, is the only viable
solution to th is increasingly dangerous situation.
(Description of Source: Pretoria-based Institute for Security Studies in
English -- Independent policy research institute providing research and
analysis of human security issues in Africa to policy makers, area
specialists, and advocacy groups. The think tank is headquartered in
Pretoria, South Africa with offices in Kenya and Ethiopia; URL:
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
5) Back to Top
Kenya Dispatches Anti-Terrorism Detectives To Help Uganda Capture
Unattributed report: "Uganda Blasts: Kenyan Detectives Join Kampala
Terrorists' Hunt" - PANA Online
T hursday July 15, 2010 09:00:37 GMT
(Description of Source: Dakar PANA Online in English -- Website of the
independent news agency with material from correspondents and news
agencies throughout Africa; URL:
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
6) Back to Top
Ugandan Police Warn Against Fresh Terror Attacks at Border Towns
Report by Dradenya Amazia: "Police Warns of Terror in Arua, Mbale" - The
New Vision Online
Thursday July 15, 2010 11:02:44 GMT
(Description of Source: Kampala The New Vision On line in English --
Website of the state-owned daily publishing a diversity of opinion; URL:
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
7) Back to Top
Shalit Counter Aid Ship Heads From Netherlands To Sderot, Gaza -- Radio
Shalit Counter Aid Ship Heads From Netherlands To Sderot, Gaza -- Radio
Israel -- KUNA Headline - KUNA Online
Wednesday June 16, 2010 10:13:50 GMT
(KUWAIT NEWS AGENCY) - GAZA, June 16 (KUNA) -- Pro-Israeli bodies in the
Netherlands are organizing a ship that is to head to Israel, carrying
humanitarian aid destined for Sderot and Gaza Strip, Radio Israel
reported.This comes as an effort to counter the anti-Israeli Freedom
Flotilla campaign trying to break the siege on Gaza and to strike and
weaken international solidarity with the strip.The ship is carrying the
name of the Israeli soldier Jilad Shalit, captured by Hamas in Gaza," with
the participation of a number of Jewish, Christian, and Muslim peace
activists, politicians, and people in media," the radio added.This
campaign is organized by members of a pro-Israeli Christian society, and
members of the Jewish community in the Netherlands, besides Dutch
intellectuals.The organizers informed the Israeli Embassy in the
Netherlands of their planned journey to Israel.Sderot is an Israeli town
located in northern Gaza Strip, and has been suffering Palestinian missile
attacks for the last eight years.(Description of Source: Kuwait KUNA
Online in English -- Official news agency of the Kuwaiti Government; URL:
Material in the World Ne ws Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of
8) Back to Top
Xinhua 'Analysis': Can Clean Energy Help Boost U.S. Employment?
Xinhua "Analysis" by Matthew Rusling: "Can Clean Energy Help Boost U.S.
Employment?" - Xinhua
Friday July 16, 2010 04:51:49 GMT
WASHINGTON, July 15 (Xinhua) -- U.S. President Barack Obama is gearing up
to pass an energy bill and jetting off to a number of locations nationwide
in a bid to drum up support for the legislation.
The president has also in recent days urged Congress to allocate spending
for clean energy projects that would reduce the nation's double-digit
jobless numbers.But critics argue that such moves will add to the nation's
mounting debt and tax future generations in exchange for only modest gains
in employment amid the worst recession since the 1930s.On Wednesday, the
president and Senate Democrats pressed for passing a bill before the
August Congressional recess. The legislation would be a less ambitious
version of what was earlier proposed and cap carbon emissions only on
power plants, rather than all industries.The move comes at a time of
sinking approval ratings on the president's handling of the economy.A CBS
News poll on Tuesday found that more than 50 percent of respondents
disapproved of how Obama is handling the economy, while 40 percent
expressed confidence in the president -- a five-point drop from last
month.Politicos said the legislation is as much about jobs creation as it
is about the environment, as the president is under pressure to reduce the
nation's double-digit unemployment figures in the face of an upcoming
Congressio nal election.Last week, Obama urged lawmakers to approve 5
billion dollars in tax additional credits for clean energy projects in a
bid to reduce unemployment while tackling climate change. The sum is more
than double the amount made available last year.The projects could
generate 40,000 jobs and boost energy independence, he said in a speech at
the University of Las Vegas.Congress, however, may be reluctant to approve
any more spending - even for the purpose of revving up the economy - as
polls show that Americans are increasingly worried about racking up too
much debt. And Congressional Democrats, who expect to lose seats in the
upcoming mid-term elections, are wary of irritating voters.On Thursday,
the president visited a soon-to-be-built battery plant in Michigan, which
he touted as the "ninth advanced battery plant to begin construction
because of our economic plan.""These plants will put thousands of people
to work," he said.On Wednesday, the White House released a report that
said the president is investing in a number of clean vehicle technologies
that are "driving down the costs associated with electric vehicles and
expanding the domestic market."Investments in batteries alone should help
lower the cost of some electric car batteries by nearly 70 percent before
the end of 2015, the report said.Thanks to these investments, U.S.
factories will be able to produce batteries and components to support up
to 500,000 electric-drive vehicles annually by 2015, which will create
"tens of thousands of American jobs," the report said.But critics blasted
the White House for what they billed as an inefficient way to create jobs
and one that will dump debt on future generations.Roger Meiners, professor
at the University of Texas at Arlington, said Obama's funds-to-jobs ratio
adds up to as much as a quarter million dollars per job."All of this is
borrowed from future generations and is piling on the deficit, " he
said.The economic impact will not pay off as much as they would if they
were directed toward improving basic infrastructure, such airports or port
facilities, he said.What is spurring Obama to support green energy
projects is the economy's weakness, the professor said, adding that
tacking on a "green" tag simply makes the idea easier to sell.But what he
called allowing bureaucrats and politicians to back certain industries is
not the same as an investor putting his or her own money on the line, he
said."The government doesn't have a good track record in picking winners,"
he said.Economists maintain that the United States needs to add more than
300,000 jobs each month just to get back to pre-recession levels of
unemployment, which could take around four years. And critics said Obama's
clean energy projects will not create anywhere near that amount of
jobs.Ethan Pollack, policy analyst at the Economic Policy Institute, said
that while Obama's clea n energy push will not singlehandedly save the
economy - and the president is not claiming it will - it represents one of
many steps that can benefit the economy not only now but also down the
road.The advantage in investing in clean technology is not only short-term
job creation but also establishment of an infant industry that will pay
dividends later, he said. One reason clean technologies are so expensive
now is because of their small market share, he said, adding that industry
expansion would drive down costs.One study commissioned by Greenpeace in
the Netherlands said the issue comes down to a "classic chicken/egg
problem: as long as demand is small, production of solar energy will
remain small-scale and expensive, and as long as the production is
small-scale and expensive, the price will remain high and the demand
small."(Description of Source: Beijing Xinhua in English -- China's
official news service for English-language audiences (New China News
Agency))< br>
Material in the World News Connection is generally copyrighted by the
source cited. Permission for use must be obtained from the copyright
holder. Inquiries regarding use may be directed to NTIS, US Dept. of


text:
or Sign in using Facebook
or Sign up using Facebook
$1 Spent = 1 point Earned Get Double Points on Prescriptions
Earn points with every dollar you spend to redeem for discounts
Get personal recommendations & stay informed about what's best for your pet's health
Results for "gastric-torsion"
20 Article(s) Available
Dogs come in all shapes and sizes, and different dog breeds can be affected by different health concerns. This list of dog breeds outlines the predisposed genetic conditions common in each breed. See what your dog might have in store, and how to prepare.
The Boxer is a happy go lucky breed that makes excellent companions with a great sense of loyalty. They can suffer from stomach and breathing problems, among others. Learn more about Boxers here.
The Poodle is prone to a number of health conditions. Learn the specific health needs of this beloved breed.
Rottweilers are excellent rescue and police dogs, as well as great life long companions. Learn the health needs of this hard-working breed here.
Bloat is the main symptom of gastric torsion, which is a very dangerous stomach condition that could be fatal if not caught quickly. Find out here what signs to look for in order to make sure your dog doesn't fall victim to a potentially deadly condition.
Purebred dogs are very popular here in the U.S. and it's important to know what health issues are common for each particular breed in order to keep your dog healthy and happy.
The title "Collie" most often refers to the Rough Collie, the breed of Lassie, famous TV starlet. Learn more about this beloved herding dog here.
Greyhounds are a sensitive breed, bred for racing. Find out their particular health needs here.
There are many dog food options to choose from on the market today. Let us help you build your dog a proper diet they'll benefit from.
Dogs can gain weight for various different reasons, like overeating, too many treats, or an underlining health issue. No matter what the reason is, an overweight dog is never a good thing and should be looked into as soon as possible. Learn what the top reasons are for overweight dogs here.
The Doberman Pinscher is one of the most loved breeds around the world, but they are subject to some health conditions. Learn about how to manage them here.
The German Shepherd has a great disposition, making them ideal family pets. Learn about health concerns this breed is prone to here.
Page: 1 of 2
Page: 1 2 View All Prev | Next


text:
Sun, Oct 14, 12 at 19:42
It's called Pyrolave and it says it has an enamel surface and it looks pretty cool. |
Here is a link that might be useful: Pyrolave enamel countertop
Follow-Up Postings:
290.00 per sq. ft. eek! |
This stuff is gorgeous! |
- Posted by desertsteph (My Page) on Mon, Oct 15, 12 at 0:52
yikes! I'd hope so for that price! |
Please Note: Only registered members are able to post messages to this forum. If you are a member, please log in. If you aren't yet a member, join now!
Return to the Kitchens Forum
Information about Posting
- You must be logged in to post a message. Once you are logged in, a posting window will appear at the bottom of the messages. If you are not a member, please register for an account.
- Please review our Rules of Play before posting.
- Posting is a two-step process. Once you have composed your message, you will be taken to the preview page. You will then have a chance to review your post, make changes and upload photos.
- After posting your message, you may need to refresh the forum page in order to see it.
- Before posting copyrighted material, please read about Copyright and Fair Use.
- We have a strict no-advertising policy!
- If you would like to practice posting or uploading photos, please visit our Test forum.
- If you need assistance, please Contact Us and we will be happy to help.
Learn more about in-text links on this page here


text:
Melampo Table LampPin It Houzz |
. |
Related Info Tools |
Design: Adrien Gardere.
The Melampo Table Lamp features an adjustable diffuser for both direct and indirect lighting. Melampo is composed of a painted zamac base with a painted aluminum stem with a silk satin fabric shade on a plastic frame. The Melampo Mini Table Lamp can be adjusted into two positions, while the Melampo Table Lamp can be adjusted into three different positions. On/off switch on cord. Available in Mini or Table sizes with grey, bronze or black fabric shades.
UL Listed.
Material(s): Aluminum
- Mini Table: 11.4375"W X 15.75"H; Base: 6.75"D
- Table: 16.625"W X 22.875"H; Base: 9.5"D
Lamp Type: INCANDESCENT
- Mini Table: 2 X 40W max 120V E12(candelabra base) G16.5 compatible incandescent, compact fluorescent or LED lamps(not included)
- Table: 2 X 75W max 120V E26(medium base) A19 compatible incandescent, compact fluorescent or LED lamps (not included)
Listing: CUL, UL
Manufacturer Specifications: Click to download specifications.
Model(s): 0315018A 0315028A 0315038A 0710018A 0710028A 0710038A
Artemide Lighting
The Artemide Group, founded by Ernesto Gismondi in 1959, operates throughout the world and aims to satisfy all lighting needs by reinforcing its position as a world leader in the lighting industry. For more than forty years, Artemide has aimed to propose light as a companion to people, both as a source of physical pleasure as well as a mental comfort. Artemide showcases products capable of meeting people's multiple needs, while offering the light performance characteristics most suited to each moment of life. Artemide offers a production structure that can offer expertise in the processing of both traditional and modern materials. The vast range of designs reflects the commitment of Artemide to provide a product that is guaranteed with an image that is strong and consistent.
Miss K Table Lamp By FlosPrice: $355.00+ Free Shipping
Spun Light T Table LampPrice: $1,195.00+ Free Shipping
Jupe Table LampPrice: $345.00+ Free Shipping
Dioscuri Table LampPrice: $260.00+ Free Shipping
Tolomeo Classic Table LampPrice: $320.00+ Free Shipping
Free shipping
on most orders
Expert advice
+ service
Best collection
of modern designs
Price guarantee
100% price match


text:
The Webster Bible (WBT) | New International Version (NIV) |
14 Thy prophets have seen vain and foolish things for thee: and they have not revealed thy iniquity, to turn away thy captivity; but have seen for thee false burdens and causes of banishment. | 14 The visions of your prophets were false and worthless; they did not expose your sin to ward off your captivity. The oracles they gave you were false and misleading. |
The Webster Bible is in the public domain. (The Webster Bible Online) | Scripture quoted by permission. Quotations designated (NIV) are from THE HOLY BIBLE: NEW INTERNATIONAL VERSION®. NIV®. Copyright © 1973, 1978, 1984 by Biblica. All rights reserved worldwide. (New International Version Bible Online) |


text:
Complete Jewish Bible (CJB) | New International Version (NIV) |
24 Now, to make a midrash on these things: the two women are two covenants. One is from Mount Sinai and bears children for slavery - this is Hagar. | 24 These things may be taken figuratively, for the women represent two covenants. One covenant is from Mount Sinai and bears children who are to be slaves: This is Hagar. |
Complete Jewish Bible Copyright 1998 by David H. Stern. Published by Jewish New Testament Publications, Inc. All rights reserved. Used by permission. (The Complete Jewish Bible Online) | Scripture quoted by permission. Quotations designated (NIV) are from THE HOLY BIBLE: NEW INTERNATIONAL VERSION®. NIV®. Copyright © 1973, 1978, 1984 by Biblica. All rights reserved worldwide. (New International Version Bible Online) |


text:
any good advice for drawing male/female bodies?
Printable View
any good advice for drawing male/female bodies?
If you visit the GB, there are a lot of artists there who can help you out in real-time.
matter of fact, I was just there.
As? I'm still on there right now...drawing lions.
i think you drew a lion next to one of my characters when I was on, lol. I was just a guest name though. I might drop in for a few minutes to sketch some bullshit. idk.
Welp, I hope the GB lesson helped you. Drop by again sometime if you need more help.
You should check this out: Anatomy: The Basics It's general anatomy advice for drawing both males and females. Also, did you get to read the anatomy tutorials here?
I'm sorry for offtopic, but what is GB? Google doesn't say anything
It's the Groupboard. Manga Tutorials Groupboard.
get a gigantic mirrow, look at ur own body or take picture of ur body. try to draw it. lol get a picture of the whole skeleton on google, trace a line amount the bones, it helps u realize where the curves are on a human body and why is it there. don't learn crazy perspective or crazy body movement yet, get the basic down. then learn about perspective/anatomy.


text:
Fajitas Grill is a place where the staff envisions families creating new memories over plates of authentic Mexican cuisine. In the cheerful space, decorated with artwork and warm colors, the kitchen staff serves up the sizzling fajitas that the spot is named for. Each dish is loaded with ingredients such as grilled steak, garden veggies, and pork with roasted pineapple. These flavorful meats and vegetables also get piled onto handmade tortillas and rolled into enchiladas. Thirsty patrons can pair meals with a glass of wine or a margarita made with smooth, oak-aged tequila.
Senor Sol's chili-slinging chefs dish up an artful menu of fiery flavors inspired by the cuisine of Zacatecas, Mexico. Warm masa, succulent meats, and fresh vegetables join forces to form edible entrees, such as the enchilada de mole, a trio of meat- and anjeo cheese-filled tortillas, basking in a homemade mole poblano sauce ($10.50). Urban ranch hands can tame wild tummies with the bistec rajas con queso, a sizzling dish of steak strips buddied up with poblano peppers and onions, then drenched in anejo cheese ($14.50). Meanwhile, the notorious chilis rellenos find their favorite hideout in mouth caves, pouring out their loot from inside fried poblano casings covered in ranchero sauce ($10.75).
Just as Thomas Edison stumbled through useless prototypes of light bulbs and movie cameras before perfecting the phonograph, the alchemists at Qdoba Mexican Grill took 47 attempts before landing on the franchise's signature blend of three cheeses, known simply as queso. That attention to detail still pervades every aspect of the menu, as employees spend hours each day chopping, dicing, and simmering the fresh ingredients that find their way into burritos, taco salads, and grilled quesadillas. Beyond the marinated bites of chicken, beef, and pork and hand-crafted tortillas, cooks protect their ripe, fragile avocados from harm by smashing them into batches of fluffy guacamole.
La Perla?s colorful dining room centers on a unique entertainment device. Whereas other restaurants simply hang up flat-screen TVs, La Perla offers diners the chance to ride a giant red chili pepper draped with a saddle. The mechanical pepper bucks riders of all ages while onlookers enjoy Guadalajara-style dishes from the menu including steak or chicken tacos, tequila-laced shrimp skewers, and sizzling fajitas, while a new indoor fireplace fuels intimate experiences. During warmer months, La Perla features two patios with an outdoor fireplace, two firepits, and party cabanas.
La Parihuela's kitchen team guides diners on a tour of the diverse taste terrains of Peru with a mouthwatering menu of national dishes. A squad of nibblers can warm up jaw muscles with selections of appetizers, such as the fish ceviche, where fish stews in lime juice and guilt over not spending enough time with its guppies. Navigate spoons through the piquant waters of the parihuela, in which an assortment of fish, crab, and mollusks leave dinners with enough shells to fashion a stylish maritime necklace. After appetizers, guests turn the pages of the menu to uncover thrilling entree conclusions to their meal, such as the lomo saltado, where french fry and rice conspirators accompany strips of tenderloin steak or chicken, or the paella, where fresh seafood bodysurfs across a crowd of rice and cilantro.
The chi masters at this trinity of acupuncture and health centers seamlessly weave Chinese medicine stretching back 3,000 years with modern medicine's focus on disease and pathology. Dr. Chuan Liu tends to patients with a parallel approach at Milwaukee Acupuncture & Health Center and Ozaukee Acupuncture & Health Center. Trained his native China, Dr. Liu helps patients manage pain and stress, restore energy, and obtain optimal health through therapies including the AcuRelief and AcuHealth systems, which he helped found.


text:
Subscribed. I love everything about this idea.
I can tell you that the first tastes after a week were like flat Guinness, but a bit sweeter. With the limited hops I used (1 oz Fuggles) i have a fairly sweet profile. Wish I would have added a few more near the end to increase the IBU's a bit.
I did a secondary with mine, and added the entire contents(the beans and their seeds and everything) hoping to get the most out of the vanilla flavor. I think it worked well but I don't have any evidence to say that it wouldn't work as well with only a primary. Guess my thought was that the beans and stuff would get lost in the thick primary trub too soon.
Guess I'm just most worried about doing the transfer since I've never done one.
That's cool. I would still urge you to up to ante on the Jameson's while you still can. With 2 cups you won't be able to detect it. Nobody that tasted mine was able to.
I didn't have an Jameson's around (i'm more of a Bushmill/Black Bush guy) so I had to use some Feckin' Irish Whisky I was given. I think I might go thro another cup in the container to up the ante a bit.
Beer? Whiskey? Combined? Yes please.
Yeah buddy! I prefer Bushmills to Jameson also, just went for the traditional car bomb. Midwest supplies sells a sort of Baileys concentrate, which I'm also considering using on my 2nd attempt.
I smelled the vanilla whisky mixture this morning... woo nelly... smells good...


text:
As a result of his early efforts, several of the nine chemical depots at which chemical weapons were stored adopted alternative disposal technologies. For example, neutralization of an agent by sodium hydroxide has been successfully used to destroy the nerve agent VX at the Newport, Indiana, chemical depot and is planned to be used to destroy mustard blister agent at the chemical depots in Pueblo, Colorado, and Blue Grass, Kentucky.
Jack contributed his time freely to professional societies. He received the 1979 Award in Chemical Engineering Practice from the American Institute of Chemical Engineers in recognition of lifetime contributions. He was involved on the governing committees of the Combustion Institute since it was founded in 1954, serving on its board of directors and a term as its president, contributing to the growth of the institute into the preeminent international organization in combustion. He was the recipient of the 1974 Alfred C. Egerton Gold Medal, awarded by the institute for distinguished, continuing, and encouraging contributions in the field of combustion. He was elected to the National Academy of Engineering in 1976.
Jack brought to his hobbies of fishing, hunting, jewelry making, and woodcarving the same intensity that he applied to his professional activities. He was an enthusiastic woodcarver who produced furniture and figurines that graced his home; he often used wood from the trunks of trees downed in his neighborhood during storms. To make hunting more competitive, he used bows that he had designed and built. He was an avid fisherman; one of his favorite spots to fish was in the Henry's fork of the Snake River in Idaho, where his cabin was situated in the Yellowstone Caldera, with a distant view of the Grand Tetons. The cabin was designed by the architect husband of his daughter Ann and was built as a joint effort by Ann and his son John, along with John's college-age friends. Jack was responsible for carving the dovetail joints for the close to 400 logs used to build the three-bedroom home, joints that locked together so perfectly that the house was impermeable and beautifully insulated. The cabin continues to be a family gathering place and continues to be enjoyed by Ann and her family.


text:
I hate it when I'm outdoors or exercising and my eyes start stinging from drippy sunscreen. What are my options? —Rachel Aydt, 40, New York City
That burning is usually caused by chemical sunscreens (ingredients listed on the Drug Facts label that end with-ate,-ene, or-one, such as ho-mosalate, octocrylene, or oxybenzone). Instead, look for a water-resistant product with physical (sometimes called mineral or natural) sunscreen, such as zinc oxide or titanium dioxide. Even with those guidelines, it can take time to find the right formula, since fragrance can also sting. We tried a few dozen, and the clear-eyed winner was—MDSolarSciences Natural Mineral Sunscreen Stick SPF 40 ($13; mdsolarsciences.com).


text:
Page 1 of 4
LUCKNOW: After handing over the mantle of Uttar Pradesh chief minister to son Akhilesh Yadav, Samajwadi Party chief Mulayam Singh Yadav can now look for a bigger role in national politics to forge a 'fourth front' comprising regional parties.
"Now that Akhilesh will be the chief minister, I will concenctrate on national politics," Mulayam said. Sources said Mulayam plans to bring together regional parties across India and form a unified front, which would be the first of its kind.
Mulayam had decided to shift his focus to national politics around 2009 Lok Sabha elections leaving Akhilesh to lead the SP's protests. Akhilesh was arrested and spent days in jail on apprehension of breach of peace.
Stay updated on the go with Times of India News App. Click here to download it for your device.
Interest Network
itimes | Email


text:
Missing Md. publisher presumed dead (AP via Yahoo! News)
A publisher and former diplomat who disappeared while sailing alone on Chesapeake Bay was presumed dead Monday after two days of searching turned up nothing but his empty sailboat, authorities said.
Link To Original Article |
All times are GMT -4. The time now is 04:21 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2015, vBulletin Solutions, Inc.
SEO by vBSEO 3.6.1
(c) Marine.com LLC 2000-2012


text:
Pioneer Park
Primary tabs
Course Details
Course Map
Course Photos
Course Reviews
There are actually two layouts for this course now, one for the summer and one for the winter. In the winter, there are a lot of sledders that use the park so the holes are adjusted to avoid conflicting uses.
I really enjoyed the course when I played it. If I hadn't met up with a couple locals I would have been completely lost as there isn't a single sign on the entire course and the only map I could find was of the old layout. Fortunately I was able to create a new map of the course as I remember it (I don't live nearby so if I made any mistakes, feel free to contact me and I'll update it).
I played the course several times and found it very enjoyable. The use of the terrain and trees was great (I think the little creek could have come into play more personally).
This is a quick course to play but still a little challenging. Has now been redesigned. Great quick course.
Courses Close By
- Diamond X, Billings MT US
- Camp on the Boulder, Mcleod MT US
- Cooke City Disc Golf Course, Cooke City MT US
- Sheltered Acres Disc Golf Course, Sheridan WY US
- Sheridan College Disc Golf Course, Sheridan WY US
- Bohart Ranch X-C Ski Center - Lower, Bozeman MT US
- Bohart Ranch X-C Ski Center - Upper, Bozeman MT US
- Mossy Pines, Bozeman MT US
- Rose Park, Bozeman MT US
- Buffalo Community Disc Golf Course, Buffalo WY US


text:
Vanguard Alta+ 263AGH Aluminum Alloy Tripod with GH-100 Pistol Grip-Head, Maximum Height 64", Supports 11 lbs
What's Included With This Item:
- GH-100 Pistol Grip-Head
- Carrying Bag
- Stone Bag
- Vanguard Limited Lifetime Warranty
Ways to Save
Why Adorama?
Easy Returns, Fast Shipping, Trusted for over 35 years.Need help? Call 800-223-2500 212-741-0052


text:
29th January 2014
Nigel Farage vows to oust councillors with 'extremist' and 'embarrassing' views from UKIP 7
3:53 PM — UKIP leader Nigel Farage has said he intends to "professionalise" his party following a number of "extremist, barmy" and "nasty" views expressed by councillors.
US: Kansas bill would allow religious business owners to refuse service to same-sex couples 5
3:21 PM — Politicians in the US state of Kansas have considered a bill which would pre-emptively allow those with "sincerely held religious beliefs" to discriminate against gay couples wishing to get married.
Lib Dem MP Stephen Gilbert to skydive for Merlin MS charity
2:02 PM — Liberal Democrat MP Stephen Gilbert is to jump out of a plane to raise money for the Merlin MS charity.
28th January 2014
NBC orders gay-themed TV series developed by Ellen DeGeneres 6
7:17 PM — US television network NBC has ordered a gay-themed series which will be developed by Ellen DeGeneres.
US: Thousands of same-sex marriage opponents and supporters to gather in Utah 7
5:51 PM — With a thousand people expected to turn out for either side, both supporters and opponents of same-sex marriage are today expected to protest in Utah.
US: Indiana House votes to remove civil unions from proposed same-sex marriage ban 1
5:18 PM — Politicians in the US state of Indiana have voted narrowly to remove a clause from a bill to ban same-sex marriage which would have also banned civil unions.
Former UKIP donor takes out newspaper ad to say: You cannot be 'homophobic' 43
3:22 PM — A former donor to UKIP has inexplicably responded to a Times columnist's article condemning a Russian anti-gay law, by taking out an advert in the Telegraph and claiming that homophobia does not exist.
Labour councillor investigated over accusations of homophobic abuse towards fellow politician 27
1:45 PM — A top Labour councillor in Rochdale is being investigated over claims that he shouted homophobic abuse at a fellow councillor.
UKIP Weather: 'It's Raining Men' 40 downloads away from re-entering Top 20 Chart
12:02 PM — A Facebook campaign to get 'It's Raining Men' to number one following the homophobic comments of a UKIP councillor may be successful as the song looks set to re-enter the Top 20.
27th January 2014
Gay Russian artist makes statement against anti-gay discrimination with 'black woman' chair parody 21
7:49 PM — A gay Russian artist has responded to a controversy involving a magazine editor who was pictured sitting on a "black woman" chair, with a parody which he says is meant as a demonstration against discrimination.
US: Indiana bill to ban same-sex marriage expected to have second House reading 2
7:28 PM — The House in the US state of Indiana is on Monday expected give a second reading to a constitutional amendment to ban same-sex marriage.
Pastor who helped woman flee US custody battle with lesbian partner appeals sentence 3
7:02 PM — Lawyers acting on behalf of a US pastor who was sentenced for helping a woman flee to Central America to escape a custody battle with her lesbian partner, have filed an appeal against his sentencing in the state of Vermont, saying he should have been sentenced elsewhere.
Kuwait: Trans women arrested under law which bans 'imitating the opposite sex' 5
6:39 PM — More than half a dozen trans women have been arrested in Kuwait for "imitating the opposite sex", in the past week.
Lawyers for NFL player say they have text messages to back up homophobia accusations against coach 2
6:16 PM — Lawyers acting on behalf of an NFL player and gay rights advocate who accused his former coach of being a "bigot" for making homophobic remarks have said they have text messages to back up the allegation.
US: Indianapolis Bar Association announces opposition to proposed same-sex marriage ban 2
5:37 PM — A proposed same-sex marriage ban in the US state of Indiana has been branded "inappropriate", by the Indianapolis Bar Association.
Gay NBA player Jason Collins to join Michelle Obama during State of the Union address 1
3:48 PM — The White House has announced that openly gay NBA player Jason Collins has been invited to join Michelle Obama during her husband's State of the Union address this week.
Elton John: Anti-gay law is 'damaging and divisive' to gay Russians and HIV campaigns 3
12:32 PM — Reflecting on time spent in Russia since the passage of a law which bans the promotion of "non-traditional relationships", Elton John has written on the "deeply dangerous and divisive" nature of the law.
25th January 2014
Football fans on gay semi-pro player coming out: 'If you live in the real world, it's not an issue' 10
8:17 AM — Fans of Gainsborough Trinity, the team of a recently out semi-professional footballer, have offered a supportive response to his announcement that he is gay.
Lance Bass offers forgiveness to TV star who said gays are 'perverts' 10
7:51 AM — Former NSYNC star Lance Bass has defended a television star who apologised after saying gay people were "more pervert", and should not be allowed on TV.
US: Virginia Republicans urge appointment of lawyers to defence of same-sex marriage ban 11
7:39 AM — Republican politicians in the US state of Virginia have asked for legal counsel to be appointed in order to defend the state's same-sex marriage ban, now that the Attorney General has said he will not.


text:
Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy.
You currently have no recent searches
An Existing Folder
A New Folder
Folder Name:
The item(s) has been successfully added to "".
Colleague's E-mail is Invalid
Your Name: (optional)
Your Email:
Colleague's Email: Separate multiple e-mails with a (;).
Message: Thought you might appreciate this item(s) I saw at Sexually Transmitted Diseases.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
Save my selection
Beachler, Daniel C.; Viscidi, Raphael; Sugar, Elizabeth A.; More
Beachler, Daniel C.; Viscidi, Raphael; Sugar, Elizabeth A.; Minkoff, Howard; Strickler, Howard D.; Cranston, Ross D.; Wiley, Dorothy J.; Jacobson, Lisa P.; Weber, Kathleen M.; Margolick, Joseph B.; Reddy, Susheel; Gillison, Maura L.; D'Souza, Gypsyamber Less
Sexually Transmitted Diseases. 42(2):93-97, February 2015.
Chow, Eric P.F.; Tomnay, Jane; Fehler, Glenda; More
Chow, Eric P.F.; Tomnay, Jane; Fehler, Glenda; Whiley, David; Read, Tim R.H.; Denham, Ian; Bradshaw, Catriona S.; Chen, Marcus Y.; Fairley, Christopher K. Less
Sexually Transmitted Diseases. 42(2):81-87, February 2015.
Espinosa, Kiana; Park, Jason A.; Gerrity, Jillian J.; More
Espinosa, Kiana; Park, Jason A.; Gerrity, Jillian J.; Buono, Sean; Shearer, Alexandria; Dick, Cindy; Mak, Mae Ling; Teramoto, Kyla; Klausner, Jeffrey D.; Pandori, Mark; Hess, David Less